Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine XR for Cannabis Use Disorder in Adolescents
NCT05957848Phase 2Recruiting
- Sponsor
- Orygen
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of guanfacine in cannabis use disorder (CUD), sponsored by Orygen. Started Jul 2023; status: recruiting.
02
Drugs
guanfacine
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT05957848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957848.